SITE005-0139

SITE005 (FRA) › SITE005-0139

SITE005-0139

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-02-13

enrolled

AEs

8

Serious

0

Dropout signal

–

Adverse events

8

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-10 (study day 202); relationship: NOT RELATED

mild assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-06 (study day 198); relationship: not assessed

moderate assessed

Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 145); relationship: not assessed

moderate assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-12-19 (study day 121); relationship: NOT RELATED

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-06 (study day 47); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed

mild assessed

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-29 (study day 40); relationship: not assessed

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-23 (study day 3); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.